Close Menu

Microsoft

US Patent 8,494,779. Method for screening essential metabolites in growth of microorganisms Inventors: Sang Yup Lee, Hawoong Jeong, Tae Yong Kim, Pan-Jun Kim, Kwang Ho Lee. Assignee: Korea Advanced Institute of Science and Technology

US Patent 8,467,974. System, method, and computer software for the presentation and storage of analysis results. Inventors: Shantanu Kaushikkar, Teresa Webster, Rui Mei, Linda McAllister. Assignee: Affymetrix

US Patent 8,417,462. System and method for identifying complex patterns of amino acids. Inventors: Samuel Bogoch, Elenore Bogoch, Samuel Winston Bogoch, Anne Elenore Borsanyi. Assignee: Not Listed

Increasing activity from sequencing vendors and other new players, as well as a flurry of activity around clinical data analysis software and the commercialization of a number of open source tools were the key trends in the bioinformatics community in 2012.

UK-based drug discovery services firm Molplex is using Microsoft’s cloud infrastructure to build its computational compound screening business.

This story originally ran on June 7.

TeraDiscoveries and Microsoft this week announced a partnership under which Microsoft will provide support and cloud computing time on its Windows Azure platform, which TeraDiscoveries will use to identify inhibitors of 25 biological targets.

US Patent 8,050,870. Identifying associations using graphical models. Inventors: David Heckerman, Jonathan Carlson, Carl Kadie. Assignee: Microsoft

IP Roundup, Jun 21, 2011

Premium

California Institute of Technology, Canon, Krassen Dimitrov, Hitachi, Fujifilm, Receptors, Wayne State University, Affymetrix, Qimoda, Microsoft

Pages

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.